Efficacy of BioNTech SE Pfizer Inc. BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] Yair Herishanu et al Blood Journal ow.ly/UZSf50F7OJM #NCT04746092 #COVID19 nCancer #CLLsm #leusm #CCC19 #COVID19 COVID-19 and Cancer Consortium (CCC19) Registry Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0%

Antibody-mediated response to the #BNT162b2 mRNA COVID-19 vaccine in patients with #CLL is markedly impaired and affected by disease activity and treatment. This trial was registered at clinicaltrials.gov as #NCT04746092 .
ashpublications.org/blood/article/…

Efficacy of BioNTech SE Pfizer Inc. BNT162b2 mRNA #COVIDVaccine in Pts w/ CLL [6/10/21] Yair Herishanu et al Blood Journal ow.ly/UZSf50F7OJM #NCT04746092 #COVID19 nCancer #CLLsm #leusm #CCC19 #COVID19 COVID-19 and Cancer Consortium (CCC19) Registry Ab response: Remission 79.2%; Tx-naive 55.2%; Active Tx 16.0%

New clinical trial: The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19 link.paperbirds.me/RsKxqH #MMSM #MultipleMyeloma #hematology

#AACR21
some COVID vaccine trials for cancer patients

The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19

Principal Investigator:Yair Herishanu, Prof.
Tel-Aviv Sourasky Medical Center

clinicaltrials.gov/ct2/show/NCT04…

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia [Jun 10, 2021] Yair Herishanu et al. Blood Journal ow.ly/UZSf50F7OJM #NCT04746092 #COVID19 nCancer #COVIDVaccine #CLLsm #leusm #CCC19 #COVID19 COVID-19 and Cancer Consortium (CCC19) Registry HT Keith Stockerl-Goldstein, MD 😷